361 related articles for article (PubMed ID: 34170745)
1. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
2. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
[TBL] [Abstract][Full Text] [Related]
3. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
4. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
Mei Q; Zhang W; Liu Y; Yang Q; Rasko JEJ; Nie J; Liu J; Li X; Dong L; Chen M; Zhang Y; Shi L; Wu H; Han W
Clin Cancer Res; 2020 Sep; 26(17):4521-4530. PubMed ID: 32499235
[TBL] [Abstract][Full Text] [Related]
6. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.
Jaffray M; Buchbinder N; Lutun A; Schneider P; Piquenot JM; Vannier JP
Ann Hematol; 2015 Aug; 94(8):1401-6. PubMed ID: 25862234
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Herrera AF; Palmer J; Martin P; Armenian S; Tsai NC; Kennedy N; Sahebi F; Cao T; Budde LE; Mei M; Siddiqi T; Popplewell L; Rosen ST; Kwak LW; Nademanee A; Forman SJ; Chen R
Ann Oncol; 2018 Mar; 29(3):724-730. PubMed ID: 29272364
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Bartlett NL; Niedzwiecki D; Johnson JL; Friedberg JW; Johnson KB; van Besien K; Zelenetz AD; Cheson BD; Canellos GP;
Ann Oncol; 2007 Jun; 18(6):1071-9. PubMed ID: 17426059
[TBL] [Abstract][Full Text] [Related]
12. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Blum KA; Jung SH; Johnson JL; Lin TS; Hsi ED; Lucas DM; Byrd JC; Cheson BD; Bartlett NL;
Ann Oncol; 2010 Nov; 21(11):2246-2254. PubMed ID: 20423913
[TBL] [Abstract][Full Text] [Related]
13. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Michallet AS; Guillermin Y; Deau B; Lebras L; Harel S; Amorin S; Reynes C; Salles G; Subtil F; Brice P
Haematologica; 2015 Jul; 100(7):e269-71. PubMed ID: 25840598
[No Abstract] [Full Text] [Related]
14. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R; Sureda A; de la Cruz F; Canales M; Gonzalez AP; Pinana JL; Rodriguez A; Gutierrez A; Domingo-Domenech E; Sanchez-Gonzalez B; Rodriguez G; Lopez J; Moreno M; Rodriguez-Salazar MJ; Jimenez-Cabrera S; Caballero MD; Martinez C
Ann Oncol; 2019 Apr; 30(4):612-620. PubMed ID: 30657848
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y
BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
